Thomas Gad is the Interim Chief Executive Officer of Y-mAbs Therapeutics, Inc., where he has been instrumental in developing innovative cancer treatments. He founded the company back in April 2015, motivated by his daughter’s battle with high-risk neuroblastoma, which adds...
Thomas Gad is the Interim Chief Executive Officer of Y-mAbs Therapeutics, Inc., where he has been instrumental in developing innovative cancer treatments. He founded the company back in April 2015, motivated by his daughter’s battle with high-risk neuroblastoma, which adds a personal touch to his commitment to the business. Thomas holds an MBA from Harvard Business School and has over 12 years of experience in the pharmaceutical industry, which includes roles in business development and senior management. In 2023, his total compensation was about $1,062,097, primarily from his salary and performance-based incentives, reflecting his significant contribution. Interestingly, Gad was appointed interim CEO on April 22, 2022, and has continued to lead the company through challenging times, including a shift in executive leadership now that he’s transitioned to Chief Business Officer. His strategic vision is not just about the science but also about connecting emotionally with the mission of the company, as he dedicates his efforts to making breakthroughs for patients with serious conditions.